Possible reduction in indinavir serum concentrations by bosentan

Ther Drug Monit. 2005 Dec;27(6):822-3. doi: 10.1097/01.ftd.0000172997.95279.77.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antihypertensive Agents / pharmacology
  • Antihypertensive Agents / therapeutic use
  • Area Under Curve
  • Bosentan
  • Drug Interactions
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Protease Inhibitors / pharmacokinetics
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Hypertension, Pulmonary / complications
  • Hypertension, Pulmonary / drug therapy
  • Indinavir / blood*
  • Indinavir / pharmacokinetics
  • Indinavir / therapeutic use
  • Male
  • Metabolic Clearance Rate
  • Sulfonamides / pharmacology*
  • Sulfonamides / therapeutic use

Substances

  • Antihypertensive Agents
  • HIV Protease Inhibitors
  • Sulfonamides
  • Indinavir
  • Bosentan